ENGN · enGene Therapeutics Inc.
$1.91
-0.04 (-2.05%)
At close · Aug 27
Market Cap
$127.95M
Shares
66.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.91
Open$1.94
Day$1.91–1.94
52W close$1.44–12.17
Avg vol 30d713K
Short int1.5M · 2.2% float · 2.2d
Short vol57%
DataFeb 2022–Aug 2026
Filing10-Q · Jun 15
Up next
FQ4-26 quarter ends
~Oct 31, 2026
Est
filed Jun 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
+6%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
−78%
trailing
YTD return
−79%
this year
Relative strength
−93%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+15% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.23% of float · ▼ -13.7% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
70 holders — near 2-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
EPS growth
+57%
Y/Y
Free cash flow
$-100.7M
Balance sheet
$50.2M
net cash
Quant / Vol
risk profile
Volatility
122%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jun 15, 2026
Restructuring costs
· second half of 2026
Initiated
$5.7M – $6.4M
Non-cash stock-based compensation expense
· second half of 2026
Initiated
$4.7M – $5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
+6%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $6 — 200d above 50d
Institutional flow
Accumulating
+15% holders QoQ · +30 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.23% of float · ▼ -13.7% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
70 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 4%
Range high $12
vs 200-day avg -67%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGN
this stock
enGene Therapeutics Inc.
|
$127.95M | -78.8% | — | — | 2.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +4.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGN | +7.9% | +8.5% | -78.0% | +6.7% | -78.9% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | +6.8% | +4.6% | -92.7% | +3.5% | -91.9% |